FibroGen

FibroGen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (HIF) biology to generate clinical programs targeting multiple therapeutic areas. FibroGen's most advanced product candidate, roxadustat (FG-4592), is an oral small molecule inhibitor of HIF prolyl hydroxylases (HIF-PHs), in Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD). Our second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer and liver fibrosis.

Type
Public
HQ
San Francisco, US
Founded
1993
Size (employees)
364 (est)+4%
FibroGen was founded in 1993 and is headquartered in San Francisco, US

FibroGen Office Locations

FibroGen has an office in San Francisco
San Francisco, US (HQ)
409 Illinois St

FibroGen Metrics

FibroGen Financial Metrics

Revenue (2016)

$179.6 m

Revenue growth (2015-16), %

(1%)

Net income (2016)

($61.7 m)

Market capitalization (21-Mar-2017)

$1.6 b

Closing share price (21-Mar-2017)

$25.1

Cash (31-Dec-2016)

$173.8 m
FibroGen's current market capitalization is $1.6 b.
FibroGen's revenue was reported to be $179.6 m in FY, 2016 which is a 1% decrease from the previous period.
FY, 2015FY, 2016

Revenue

$180.8 m$179.6 m

Revenue growth, %

(1%)

R&D expense

$214.1 m$187.2 m

General and administrative expense

$44.4 m$46 m

Operating expense total

$258.5 m$233.2 m

EBIT

($77.6 m)($53.7 m)

EBIT margin, %

(43%)(30%)

Interest expense

($11 m)($10.7 m)

Pre tax profit

($85.5 m)($61.8 m)

Income tax expense

$242 k($71 k)

Net Income

($85.8 m)($61.7 m)
FY, 2015FY, 2016

Cash

$153.3 m$173.8 m

Current Assets

$200.6 m$266.5 m

PP&E

$129 m$123.7 m

Total Assets

$470.6 m$469.6 m

Accounts Payable

$72 m

Current Liabilities

$67.2 m$65.1 m

Additional Paid-in Capital

$586.6 m$625.9 m

Retained Earnings

($408.1 m)($469.7 m)

Total Equity

$177.6 m$155.8 m

Financial Leverage

2.7 x3 x
FY, 2015FY, 2016

Net Income

($85.8 m)($61.7 m)

Depreciation and Amortization

$5.7 m$6 m

Cash From Operating Activities

($18.6 m)$7.1 m

Purchases of PP&E

($2 m)($1.3 m)

Cash From Investing Activities

($5.9 m)$6.6 m

Cash From Financing Activities

$12.3 m$6.7 m

FibroGen Market Value History

FibroGen Company Life

You may also be interested in